For millions of Americans who depend on insulin to manage diabetes, a federal cap on out-of-pocket insulin costs has offered substantial financial relief. Under provisions that took effect as part of the Inflation Reduction Act, Medicare beneficiaries saw their insulin copays capped at $35 per month per prescription, a change that, according to early reports, has saved some patients hundreds of dollars each month depending on what they were previously paying. For someone with dementia who also manages diabetes — a common overlap, since diabetes is a recognized risk factor for cognitive decline — this law has the potential to ease one of the most persistent financial burdens in their care. This article breaks down what the insulin cap law covers, who qualifies, and where the savings are real versus where gaps remain.
We will also look at why this matters specifically for older adults and people living with dementia, how caregivers can ensure their loved ones are benefiting, and what limitations still exist for those on private insurance or without coverage. If you or someone you care for uses insulin, understanding these provisions is essential to making sure you are not overpaying. The intersection of diabetes management and cognitive health makes this more than a pocketbook issue. Poor diabetes control has been linked in research to accelerated cognitive decline, and when medication costs force patients to ration insulin — a well-documented and dangerous practice — the consequences ripple outward into brain health, hospitalization risk, and caregiver burden.
Table of Contents
- How Much Are Patients Actually Saving Under the Insulin Cap Law?
- Who Qualifies for the $35 Insulin Cap and Who Gets Left Behind
- Why Insulin Costs Matter More When Dementia Is in the Picture
- How Caregivers Can Make Sure the Savings Are Actually Applied
- Gaps in Coverage and What the Law Does Not Fix
- State-Level Insulin Caps and How They Interact with Federal Law
- What Comes Next for Insulin Affordability and Chronic Disease Management
- Conclusion
- Frequently Asked Questions
How Much Are Patients Actually Saving Under the Insulin Cap Law?
The savings vary considerably depending on what a patient was paying before the cap took effect. Historically, some Medicare beneficiaries reported paying $100 to $400 or more per month for insulin out of pocket, depending on their plan, the type of insulin prescribed, and whether they had hit their deductible. With the $35 monthly cap per covered insulin product, patients who were previously in higher cost tiers have seen the most dramatic reductions. A patient who was paying $200 per month for a single insulin prescription, for example, would see a savings of roughly $165 per month, or nearly $2,000 over the course of a year. However, it is important to note that not every insulin user was paying exorbitant prices before the cap.
Some patients with generous Part D plans or those who qualified for manufacturer discount programs were already paying close to $35 or less. For those individuals, the law functions more as a safety net than an immediate windfall. The real impact has been felt most acutely by patients who were caught in the coverage gap — sometimes called the “donut hole” — or who were on plans with high coinsurance percentages for specialty drugs. As of recent reports, the cap applies to insulin products covered under Medicare Part D and, following subsequent provisions, to insulin furnished through Part B as well, such as insulin used with durable medical equipment like insulin pumps. This distinction matters for patients with dementia who may use different delivery methods depending on their care setting and level of independence.
Who Qualifies for the $35 Insulin Cap and Who Gets Left Behind
The $35 monthly cap initially applied specifically to Medicare beneficiaries. This includes people aged 65 and older, as well as younger individuals on Medicare due to disability. For the millions of seniors managing both diabetes and cognitive conditions like Alzheimer’s disease or vascular dementia, this coverage is directly relevant. If your loved one is on Medicare and uses insulin, they should already be benefiting from this cap without needing to take any special action — the cost limitation is applied automatically at the pharmacy. However, if someone is on private insurance, the situation has been more complicated.
Some states have enacted their own insulin price caps for state-regulated insurance plans, but the specifics vary widely by state, and self-insured employer plans — which cover a large share of the privately insured population — are generally not subject to state insurance mandates. This means a 58-year-old with Type 2 diabetes and early-stage cognitive impairment who gets insurance through a large employer may not benefit from any cap at all, depending on their plan structure and state of residence. There is also a gap for uninsured patients. The federal law does not establish a price cap for people who pay cash for insulin or who lack insurance coverage entirely. Some manufacturers have voluntarily capped prices — Eli Lilly, for instance, announced a $35 cap on its most commonly prescribed insulins — but these voluntary programs can change and are not guaranteed long-term. Caregivers should verify current pricing directly with manufacturers or pharmacies rather than assuming a cap applies.
Why Insulin Costs Matter More When Dementia Is in the Picture
Diabetes and dementia share a troubling relationship that makes insulin affordability a brain health issue, not just an endocrine one. Research, including large longitudinal studies, has consistently shown that people with poorly controlled Type 2 diabetes face a significantly elevated risk of developing Alzheimer’s disease and other forms of dementia. Some researchers have even referred to Alzheimer’s as “Type 3 diabetes” because of the role insulin resistance appears to play in brain function, though this terminology remains debated in the medical community. When insulin costs are prohibitively high, patients ration their doses. They skip injections, use less than prescribed, or stretch vials beyond their recommended use. A survey published before the cap took effect found that a notable percentage of insulin users reported rationing behavior tied to cost.
For an older adult already experiencing mild cognitive impairment, this rationing can be catastrophic. blood sugar swings — both hyperglycemia and hypoglycemia — are associated with acute confusion, increased fall risk, and faster cognitive decline. A caregiver managing a parent with both diabetes and dementia may find that stabilizing insulin access is one of the single most impactful interventions for preserving their loved one’s remaining cognitive function. Consider a scenario that plays out in families across the country: an 80-year-old with moderate Alzheimer’s who also takes long-acting insulin. Before the cap, their adult child was juggling the cost of memory care, home health aides, and $180 monthly insulin copays. The financial pressure led to occasional skipped doses, which led to emergency room visits for dangerously high blood sugar, which in turn accelerated confusion and behavioral symptoms. The $35 cap does not solve every problem in that picture, but it removes one of the pressure points that was making everything else worse.
How Caregivers Can Make Sure the Savings Are Actually Applied
If you are a caregiver for someone on Medicare who uses insulin, the cap should be applied automatically at the point of sale — the pharmacy. You should not need to enroll in a separate program or submit paperwork. That said, billing errors happen, and they happen more frequently than most people realize in the pharmacy and insurance world. It is worth checking every receipt and explanation of benefits statement to confirm that no insulin copay exceeds $35 for a month’s supply. If you notice charges above $35, the first step is to contact the Part D plan directly. In some cases, the issue is a lag in plan updates or a formulary classification error.
If the plan is not responsive, the Medicare helpline (1-800-MEDICARE) can intervene. For patients with dementia, caregivers with legal authority — such as power of attorney or healthcare proxy — may need to navigate these calls on the patient’s behalf, which can add a layer of complexity but is well within their rights. The tradeoff to be aware of is that the $35 cap applies per insulin prescription per month, not as a blanket cap across all insulin products. A patient who uses both a long-acting and a rapid-acting insulin could face two separate $35 copays, totaling $70 per month. That is still likely less than what many patients were paying before, but it is not the single flat $35 some people assume when they first hear about the law. Caregivers managing complex medication regimens should add up all insulin-related costs to get the true picture.
Gaps in Coverage and What the Law Does Not Fix
The $35 cap is a meaningful step, but it does not address the underlying list price of insulin, which remains high in the United States compared to other countries. The cap shifts the cost burden rather than eliminating it — insurers and Medicare plans absorb the difference, which can affect premiums, formulary decisions, and plan availability over time. Some health policy analysts have raised concerns that if plans face higher costs for covering insulin, they may adjust by increasing premiums or reducing coverage in other drug categories, potentially affecting other medications that dementia patients rely on. Another limitation is that the law does not cap the cost of insulin-related supplies. Test strips, continuous glucose monitors, syringes, pen needles, and insulin pump supplies can collectively cost as much as or more than the insulin itself.
For a patient with dementia who requires a continuous glucose monitor because they cannot reliably check their own blood sugar, these supply costs are not trivial, and they are not covered by the $35 cap. There is also a timing concern. Legislation and healthcare policy can shift with new administrations and congressional priorities. While the insulin cap provisions have broad bipartisan support at the public level, the specifics of implementation, the scope of coverage, and the potential expansion to private insurance are all subject to ongoing political and regulatory processes. Caregivers should stay informed through reliable sources such as Medicare.gov and the Centers for Medicare and Medicaid Services rather than relying on secondhand summaries that may be outdated.
State-Level Insulin Caps and How They Interact with Federal Law
Several states had already enacted their own insulin copay caps before the federal provisions took effect, creating a patchwork of protections. States like Colorado, which was among the first to pass a $100-per-month insulin cap for state-regulated plans, demonstrated early proof that such caps were politically viable and practically implementable. Other states have followed with their own versions, some with lower caps and some with broader coverage.
For patients who have both Medicare and a state-regulated supplemental plan, the federal $35 cap generally takes precedence for Medicare-covered insulin. But for those on private plans regulated at the state level, the applicable cap depends on state law, plan type, and whether the employer’s plan is self-insured. Caregivers juggling multiple insurance sources for a loved one with dementia should consult directly with each plan to understand which cap applies and whether any additional savings programs are available.
What Comes Next for Insulin Affordability and Chronic Disease Management
Looking ahead, the broader conversation around drug pricing in the United States continues to evolve. The insulin cap has been widely cited as a model for potential price controls on other high-cost medications, and there is active discussion about extending similar caps to the private insurance market at the federal level. For the dementia care community, any expansion that reduces medication costs for older adults managing multiple chronic conditions would be significant.
The connection between metabolic health and brain health is also gaining more attention in research circles. As our understanding of how insulin resistance contributes to neurodegeneration deepens, the case for making insulin affordable and accessible grows even stronger. Ensuring that every patient — particularly those whose cognitive decline may prevent them from advocating for themselves — can access this medication without financial hardship is not just good health policy. It is a matter of basic dignity in care.
Conclusion
The federal insulin cap has delivered real savings for Medicare beneficiaries, potentially reducing out-of-pocket costs by hundreds of dollars per month for patients who were previously paying the most. For families managing the dual burden of diabetes and dementia, this financial relief can translate directly into better health outcomes, fewer emergency visits, and more stable day-to-day cognitive function. The key is ensuring the cap is being properly applied and understanding its limits — it does not cover supplies, it applies per prescription, and it does not yet universally extend to private insurance.
Caregivers should check pharmacy receipts, contact Medicare or their loved one’s plan with any billing discrepancies, and stay informed about both federal and state-level protections. Affordable insulin is not a luxury for people managing chronic disease and cognitive decline — it is a medical necessity that directly affects quality of life, safety, and the trajectory of brain health. If you have not reviewed your loved one’s insulin costs recently, now is a practical time to do so.
Frequently Asked Questions
Does the $35 insulin cap apply to all types of insulin?
The cap applies to insulin products covered under Medicare Part D and Part B. However, not every insulin product may be on every plan’s formulary. If a specific insulin brand or formulation is not covered by the plan, the cap may not apply to that product, and the patient may need to switch to a covered alternative or file an exception request.
Do I need to sign up for anything to get the $35 cap?
No. For Medicare beneficiaries, the cap is applied automatically at the pharmacy. You do not need to enroll in a separate program. However, you should verify that charges are correct on your receipts and explanation of benefits statements.
Does the cap apply if my family member is on Medicaid, not Medicare?
Medicaid programs generally already had lower insulin copays or no copays, depending on the state. The $35 cap was specifically designed to address Medicare Part D costs. Medicaid beneficiaries should check with their state Medicaid program for the most current copay information.
What if my loved one with dementia uses an insulin pump — is that insulin covered?
Insulin furnished through durable medical equipment, such as an insulin pump, is typically covered under Medicare Part B rather than Part D. The $35 cap provisions have been extended to include Part B insulin as well, but the administrative pathway is different. Confirm coverage directly with the plan or equipment supplier.
Can someone with dementia be helped by a caregiver at the pharmacy to ensure the cap is applied?
Yes. A caregiver with appropriate legal authority, such as power of attorney, can communicate with pharmacies and insurance plans on behalf of the patient. Even without formal legal documents, many pharmacies will work with known family caregivers on billing questions, though formal authorization is recommended for insurance disputes.
